Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/16881

Title: Model based estimates of long-term persistence of inactivated hepatitis: A vaccine-induced antibodies in adults
Authors: HENS, Niel
Hardt, Karin
Van Damme, Pierre
Van Herck, Koen
Issue Date: 2014
Citation: VACCINE, 32 (13), p. 1507-1513
Abstract: Background: In this paper, we review the results of existing statistical models of the long-term persistence of hepatitis A vaccine-induced antibodies in light of recently available immunogenicity data from 2 clinical trials (up to 17 years of follow-up). Methods: Healthy adult volunteers monitored annually for 17 years after the administration of the first vaccine dose in 2 double-blind, randomized clinical trials were included in this analysis. Vaccination in these studies was administered according to a 2-dose vaccination schedule: 0, 12 months in study A and 0, 6 months in study B (NCT00289757/NCT00291876). Antibodies were measured using an in-house ELISA during the first 11 years of follow-up; a commercially available ELISA was then used up to Year17 of follow-up. Long-term antibody persistence from studies A and B was estimated using statistical models for longitudinal data. Data from studies A and B were modeled separately. Results: A total of 173 participants in study A and 108 participants in study B were included in the analysis. A linear mixed model with 2 change points allowed all available results to be accounted for. Predictions based on this model indicated that 98% (95%CI: 94–100%) of participants in study A and 97% (95%CI:94–100%) of participants in study B will remain seropositive 25 years after receiving the first vaccine dose. Other models using part of the data provided consistent results: ≥95% of the participants was projected to remain seropositive for ≥25 years. Conclusion: This analysis, using previously used and newly selected model structures, was consistent with former estimates of seropositivity rates ≥95% for at least 25 years.
URI: http://hdl.handle.net/1942/16881
DOI: 10.1016/j.vaccine.2013.10.088
ISI #: 000335617600014
ISSN: 0264-410X
Category: A1
Type: Journal Contribution
Validation: ecoom, 2015
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
N/A1.06 MBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.